Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2-Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study (vol 35, pg 141, 2017)

被引：1
|
作者：
Perez
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷 / 20期
关键词：
D O I：
10.1200/JCO.2017.74.3971
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：2342 / 2342
页数：1
相关论文
共 50 条
  • [41] Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer
    Hurley, J
    Doliny, P
    Reis, I
    Silva, O
    Gomez-Fernandez, C
    Velez, P
    Pauletti, G
    Pegram, MD
    Slamon, DJ
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (12) : 1831 - 1838
  • [42] Randomized Phase III Trial of Trastuzumab Plus Capecitabine With or Without Pertuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Who Experienced Disease Progression During or After Trastuzumab-Based Therapy
    Urruticoechea, Ander
    Rizwanullah, Mohammed
    Im, Seock-Ah
    Sanchez Ruiz, Antonio Carlos
    Lang, Istvan
    Tomasello, Gianluca
    Douthwaite, Hannah
    Crnjevic, Tanja Badovinac
    Heeson, Sarah
    Eng-Wong, Jennifer
    Munoz, Montserrat
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (26) : 3030 - +
  • [43] Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial
    Piccart-Gebhart, Martine
    Holmes, Eileen
    Baselga, Jose
    de Azambuja, Evandro
    Dueck, Amylou C.
    Viale, Giuseppe
    Zujewski, Jo Anne
    Goldhirsch, Aron
    Armour, Alison
    Pritchard, Kathleen I.
    McCullough, Ann E.
    Dolci, Stella
    McFadden, Eleanor
    Holmes, Andrew P.
    Liu Tonghua
    Eidtmann, Holger
    Phuong Dinh
    Di Cosimo, Serena
    Harbeck, Nadia
    Tjulandin, Sergei
    Im, Young-Hyuck
    Huang, Chiun-Sheng
    Dieras, Veronique
    Hillman, David W.
    Wolff, Antonio C.
    Jackisch, Christian
    Lang, Istvan
    Untch, Michael
    Smith, Ian
    Boyle, Frances
    Xu, Binghe
    Gomez, Henry
    Suter, Thomas
    Gelber, Richard D.
    Perez, Edith A.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (10) : 1034 - +
  • [44] Pertuzumab Monotherapy After Trastuzumab-Based Treatment and Subsequent Reintroduction of Trastuzumab: Activity and Tolerability in Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer
    Cortes, Javier
    Fumoleau, Pierre
    Bianchi, Giulia Valeria
    Petrella, Teresa M.
    Gelmon, Karen
    Pivot, Xavier
    Verma, Shailendra
    Albanell, Joan
    Conte, Pierfranco
    Lluch, Ana
    Salvagni, Stefania
    Servent, Veronique
    Gianni, Luca
    Scaltriti, Maurizio
    Ross, Graham A.
    Dixon, Joanna
    Szado, Tania
    Baselga, Jose
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (14) : 1594 - 1600
  • [45] Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer
    Liberato, Nicola Lucio
    Marchetti, Monia
    Barosi, Giovanni
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (06) : 625 - 633
  • [46] Tailored duration of adjuvant trastuzumab for human epidermal growth factor receptor 2-positive breast cancer
    Ke-Da Yu
    Xin Wang
    Wan-Kun Chen
    Lei Fan
    Miao Mo
    Han Chen
    npj Precision Oncology, 4
  • [47] Tailored duration of adjuvant trastuzumab for human epidermal growth factor receptor 2-positive breast cancer
    Yu, Ke-Da
    Wang, Xin
    Chen, Wan-Kun
    Fan, Lei
    Mo, Miao
    Chen, Han
    NPJ PRECISION ONCOLOGY, 2020, 4 (01)
  • [48] A phase 1 study of weekly dosing of trastuzumab emtansine (T-DM1) in patients with advanced human epidermal growth factor 2-positive breast cancer
    Beeram, Muralidhar
    Krop, Ian E.
    Burris, Howard A.
    Girish, Sandhya R.
    Yu, Wei
    Lu, Michael W.
    Holden, Scott N.
    Modi, Shanu
    CANCER, 2012, 118 (23) : 5733 - 5740
  • [49] Prolonged Responses With Trastuzumab Emtasine Treatment of Human Epidermal Growth Factor Receptor 2-positive Metastatic Breast Cancer Refractory to Trastuzumab and Pertuzumab: Systematic Review of Evidence
    Martin Huertas, Roberto
    Fernandez Abad, Maria
    Corral de la Fuente, Elena
    Serrano Domingo, Juan Jose
    Martinez Janez, Noelia
    CLINICAL BREAST CANCER, 2021, 21 (05) : 391 - 398
  • [50] Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer (vol 24, pg 1831, 2006)
    Hurley, Judith
    Doliny, Philomena
    Reis, Isildinha
    Silva, Orlando
    Gomez-Fernandez, Carmen
    Velez, Pedro
    Pauletti, Giovanni
    Powell, Jodeen E.
    Pegram, Mark D.
    Slamon, Dennis J.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (21) : 3515 - 3515
12345